Aegerion Pharma (AEGR) Posts Smaller-than-Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Leerink Partners Reiterates Outperform on Aegerion Pharma (AEGR) - PT to $15
February 26, 2016 8:01 AM ESTLeerink Partners maintained an Outperform rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and cut the price target to $15.00 (from $31.00), following the company's 4Q earnings report.
Analyst Joseph Schwartz commented, "Maintain OP following a huge reset in expectations, lowering PT to $15 to factor in a... More
